Orthobiologics for Musculoskeletal Soft Tissue Replacement and Regeneration
The demand for orthobiologics for musculoskeletal soft tissue replacement and regeneration continues to grow. In 2022, global sales of these products totaled approximately $2.3bn. Key factors driving growth in this market include the incidence of sports and traumatic injuries, as well as the demand for readily available treatments for posttraumatic osteoarthritis and chronic tendinitis. Limiters to market growth include the high price of implants and a limited supply of donated human tissue.
This new report from Meddevicetracker includes a discussion of products, current/forecast markets, competitors, and opportunities in the global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration. This market is segmented by product type (including products for cartilage replacement and regeneration, meniscus replacement and regeneration, and ligament and tendon replacement and regeneration). Regions covered by this analysis include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2022–27.
If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].
See these related Medtech Insight articles on orthobiologics: